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at Chapel Hill, Chapel Hill, NC, USAA B S T R A C TObjectives: To systematically review the cost-effectiveness of diabe-
tes interventions, identify high-value diabetes services, and estimate
potential gains from increasing their utilization. Methods: The study
consisted of two steps. First, we reviewed cost-utility analyses (CUAs)
related to diabetes published through the end of 2012, using the Tufts
Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.
org). We used logistic regression to examine factors independently
associated with favorable cost-effective ratios. Second, we used the
Humedica electronic medical records to estimate potential savings
and health beneﬁts gained by shifting patients currently receiving
low-value services to high-value alternatives. Results: We identiﬁed
196 diabetes CUAs, of which 55% examined pharmaceuticals. Most
(70%) diabetes CUAs focused on treatment rather than prevention.
Most used a health care payer perspective and were industry-
sponsored. Of the 497 published cost-utility ratios, 82% examined an
intervention recommended by diabetes guidelines. Approximately
73% of the interventions were cost-saving or below $50,000 peree front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2014.12.004
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s, Tufts Medical Center, 800 Washington Street, Bquality-adjusted life-year. Logistic regression analysis showed that
higher-quality CUAs, CUAs conducted from the US perspective,
surgical interventions, and guideline-recommended interventions
were more likely to report favorable ratios. Of the 7907 eligible
patients with diabetes in our sample, up to 7117 could in principle
be shifted to cost-saving treatments, reducing costs by $12.5 million
and gaining more than 1938 quality-adjusted life-years over a lifetime.
Conclusions: Most diabetes interventions evaluated by CUAs are
recommended by practice guidelines and may provide good value
for money. Our results indicate that patients with diabetes and the
health care system could potentially beneﬁt from shifting to the
greater use of high-value services.
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systematic review.
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It is well documented that diabetes places a substantial economic
burden on patients and the health care system [1–3]. In the United
States, costs associated with prediabetes and diabetes have
increased from $174 billion in 2007 to $245 billion in 2012, including
$176 billion direct medical costs and $69 billion indirect costs due to
related disability and lost productivity [1]. Spending on diabetes
accounts for more than one in ﬁve US health care dollars and, on
average, people with diabetes spend 2.3 times more on health care
services [1,2]. Diabetes also imposes a substantial burden on
patients’ quality of life and reduces life expectancy because it
increases the risk of chronic complications, such as cardiovascular
diseases, kidney diseases, and eye and foot problems [3]. It is one of
the top 10 leading causes of death in the United States, and thenumber of afﬂicted patients has increased substantially in the past
5 years, from 17.5 million in 2007 to 22.3 million in 2011 [2].
Cost-effectiveness analysis (CEA) is a widely used methodology
for assessing the value of health care interventions. CEA compares
a health care intervention to a comparator, reporting the interven-
tion’s performance in the form of an incremental cost-effectiveness
ratio (ICER). The ICER’s numerator represents the intervention’s
incremental cost, whereas the ICER’s denominator represents its
incremental health beneﬁt. A small ICER indicates that the inter-
vention is favorable because it indicates that it produces health
units of health inexpensively. A CEA may also ﬁnd that an
intervention is “cost-saving” (reduces costs and improves health)
or that it is “dominated” (increases costs and makes health worse).
Several systematic reviews have surveyed the diabetes inter-
vention CEA literature [4–8]. Klonoff and Schwartz [4] reviewedon behalf of International Society for Pharmacoeconomics and
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 0 8 – 3 1 4 309CEAs on 17 widely practiced diabetes interventions and found that
most interventions were cost-saving or cost-effective. Zhang et al.
[5] updated this study by adding CEAs on diabetes prevention and
screening, as well as studies on the economic cost of diabetes.
They emphasized the importance of efﬁciently using resources on
cost-effective interventions. Raikou and McGuire [6] and Vijgen
et al. [7] reviewed economic evaluations of interventions for type 2
diabetes. A more recent review by Li et al. [8] described 56 CEAs
published through 2008 that evaluated interventions recom-
mended by the American Diabetes Association (ADA) to prevent
and control diabetes. They concluded that preventive interventions
were cost saving or highly cost-effective and hence should be
prioritized by policymakers.
Compared with earlier studies, this analysis is more compre-
hensive, reviewing a total of 196 articles, providing more
detailed information on the articles reviewed, and placing these
ﬁndings in broader perspective by using real-world data to
demonstrate savings at the health care system level. Our study
is composed of a systematic review and a “what-if” analysis.
First, we systematically review cost-utility analyses (CUAs), a
subgroup of CEAs that quantify health beneﬁts in terms of
quality-adjusted life-years (QALYs). A QALY is a generic measure
that reﬂects both length of life and morbidity. It has been used in
studies evaluating interventions addressing a wide range of
health conditions [9]. Our analysis covers diabetes-related CUAs
published in peer-reviewed, English-language journals through
2012. As part of this review, we also examine factors associated
with favorable cost-effectiveness. Second, we identify “high-
value” diabetes services (e.g., cost-saving) and estimate potential
gains from increasing their utilization. The purpose was to
assess the impact of hypothetical resource reallocation scenarios
on costs and health beneﬁts gained. We acknowledge at the
outset that this is an exploratory analysis, and the main objec-
tive was to demonstrate potential gains from optimal use
of high-value services and to show applications of CUAs using
real-world data.Methods
Step 1: Systematic Review
Data: The Tufts Medical Center Cost-Effectiveness Analysis
Registry
We analyzed information on CUAs cataloged in the Tufts Medical
Center Cost-Effectiveness Analysis Registry (available at http://
www.cearegistry.org), a comprehensive database with more than
3600 CUAs and 9800 cost-utility ratios published in the peer-
reviewed literature from 1976 through the end of 2012. The registry
contains information extracted from CUA articles published in
English. The registry researchers identify articles for inclusion in
the registry by searching MEDLINE using the keywords “QALY,”
“quality-adjusted,” and “cost-utility analysis.” Two trained readers
independently review all articles to be included in the registry (see
Appendix 1 in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2014.12.004 for more details of search strategies). The
readers summarize the study methodology, the reported cost-
effectiveness ratios, and all utility weights used in the article [10–
15]. Registry ICERs are standardized so that they are expressed in
terms of 2012 US dollars.
We included Tufts registry articles pertaining to any of the
following three disease categories: diabetes mellitus, endocrine
disorders, and other disorders. We then reviewed the titles and
abstracts and selected articles focusing on diabetes-related
interventions. Selected interventions covered type 1 diabetes,
type 2 diabetes, gestational diabetes mellitus, and complications
of diabetes. Only those CUAs that correctly conductedincremental analyses were included. We excluded reviews,
editorials, and other types of economic studies such as cost-
beneﬁt analysis and CEAs using other health measures (e.g.,
hemoglobin A1c level).
Analysis: Systematic review of diabetes CUAs
We reported the results of the systematic review in two ways. First,
we summarized the study characteristics. We grouped the articles
on the basis of prevention stage: primary prevention (interventions
that protect healthy people from the onset of diabetes and its
complications), secondary prevention (interventions that mitigate the
progression of diabetes and its complications during the early
stages of the disease), and tertiary prevention (interventions that
treat or manage patients with diabetes). We recorded the following
key study features: 1) publication year; (2) country of study (the
country to which the results are applied); 3) type of study funding
or sponsorship (industry, nonindustry, unfunded, or not speciﬁed);
4) intervention type (e.g., pharmaceutical, screening, medical
device, or surgical); 5) the analytic perspective (societal, health care
payer, or other); 6) whether the study explicitly and clearly
speciﬁed the analytic time horizon, the intervention, the compa-
rator, and the target population; 7) whether the study conducted a
sensitivity analysis; 8) evaluation of the study’s overall quality
(scored 1–7); and 9) whether the intervention was recommended by
either the 2011 American Association of Clinical Endocrinologists
(AACE) medical guidelines [16] or the 2012 ADA standards of
medical care in diabetes [17]. Study quality was evaluated on the
basis of factors such as the reasonableness of assumption, overall
presentation quality, the completeness and clarity of methods,
including the model used, data sources, costs, utility, ratios, and
characterization of uncertainty.
The second set of analyses examined the distribution of
ICERs. We classiﬁed ICERs as cost-saving (less costly, more
effective)—less than $20,000/QALY, $20,000 to $50,000/QALY,
$50,000 to $100,000/QALY, $100,000 to $200,000/QALY, more than
$200,000/QALY—and dominated (more costly, less effective),
similar to the classiﬁcation used by Li et al. [8]. We used logistic
regression to investigate whether ratio favorability (e.g., having a
value less than the median for all diabetes-related ICERs) is
predicted by variables such as country (US vs. non-US), type of
sponsorship, intervention type, prevention stage, study perspec-
tive (societal vs. nonsocietal), study quality (dichotomized), or
whether the intervention is recommended by either the 2011
AACE guidelines or the 2012 ADA standards. The analysis
assigned each ratio a statistical weight of 1/n, where n was the
number of ratios reported by that ratio’s article. This approach
ensures that no single article disproportionately affects the
results by virtue of its reporting a large number of ratios [18].
Step 2: Resource Reallocation Scenarios
Data: Humedica electronic medical records
We used the 2008-2012 Humedica electronic medical record (EMR)
data sets to help quantify the utilization of various diabetes-related
services identiﬁed in the Tufts Medical Center Cost-Effectiveness
Analysis Registry as providing good value for money. Humedica is
one of the largest EMR databases in the United States that includes
clinical and health care utilization data from a network of provider
organizations covering nearly 30 million patients across 38 states
(www.humedica.com). It is a patient-level clinical data set that
combines encounter data, clinical details, and prescription records
in patients’ EMRs. As described below, we used the Humedica EMR
data to estimate intervention utilization rates, and identiﬁed
around 400,000 patients in the Humedica EMR with diagnoses of
diabetes, including type 1 diabetes (3%), type 2 diabetes (53%), and
other types of diabetes (prediabetes, gestational diabetes mellitus,
and unknown diabetes type) (44%).
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interventions
We used the Humedica EMR data to estimate the potential
number of patients who could be switched to high-value (cost-
saving) diabetes services and treatments identiﬁed in our review
of the Tufts Medical Center Cost-Effectiveness Analysis Registry
and recommended by the AACE guidelines or the ADA standards.
We assumed that patients were candidates for these high-value
services if the Humedica data indicated that they were currently
using a substitute diabetes-related service that achieved inferior
health outcomes (fewer QALYs) at a higher cost.
From the US health care payer perspective, we estimated
potential cost savings and QALY gains by simulating a hypo-
thetical shift of these patients to high-value interventions.
Recognizing that not all patients would in reality be eligible
because services must be tailored to avoid adverse drug events,
we explored the implications of shifting a range of appropriate
patients using low-value interventions (10%–90%) [19]. We also
reviewed the comparative effectiveness research (CER) literature
to ensure that there was clinical evidence to support the idea that
these shifts could be accomplished safely and that they would
improve effectiveness.
We estimated total savings as the product of the number of
patients shifted to the new intervention and the per-person
reduction in lifetime costs. Similarly, we estimated total health
gain as the product of the size of this population and the per-
person lifetime QALY gains. Per- person cost savings and QALY
gains came from the CUA studies, with cost estimates based on
direct medical costs only. We standardized all costs by converting
them to 2012 US dollars. All analyses were performed using SAS,
version 9.3 (Cary, NC).Results
Step 1: Characteristics of Diabetes-Related CUAs
We identiﬁed 312 CUAs on endocrine disorders in the registry. One
hundred sixteen articles were excluded because they either per-
tained to endocrine disorders other than diabetes or did not reportFig. 1 – Selection of diabetes cost-utility studies for systematic r
analysis.a valid ratio. The ﬁnal sample included 196 articles and 497 ICERs
(see Appendix 2 in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2014.12.004 for a reference list of 196 diabetes
CUAs) (Fig. 1). The annual number of diabetes CUA publications
increased markedly over time, from 7 published before 1997 to 120
published from 2008 to 2012 (Table 1). Most diabetes CUAs focused
on tertiary prevention (n ¼ 138, 70%). The published articles were
frommore than 20 countries, of which 41% (n ¼ 80) were US-based.
The most commonly assessed diabetes interventions included
pharmaceuticals (n ¼ 107, 55%), health education programs (n ¼
34, 17%), and delivery of care (n ¼ 33, 17%). Most (n ¼ 140, 71%) of
the CUAs presented results from the health care payer perspective,
regardless of prevention stage. Industry was the most common
source of funding among studies evaluating secondary (n ¼ 21,
49%) and tertiary (n ¼ 79, 57%) prevention measures. In contrast, of
the 15 studies evaluating primary prevention, more than half (n ¼
9, 60%) reported nonindustry sponsorship, whereas the rest (n ¼ 4,
27%) did not disclose their sponsorship.
As recommended by CEA guidelines [10–15], most of the
diabetes CUAs explicitly speciﬁed the time horizon (n ¼ 188,
96%), the intervention (n ¼ 192, 98%), the comparator (n ¼ 190,
97%), and the target population (n ¼ 192, 98 %). A total of 96% (n ¼
188) of the studies performed sensitivity analyses. The average
study quality score was 4.5 for diabetes CUAs, which was slightly
higher than the average quality rating (4.4) for all studies in the
Tufts Medical Center Cost-Effectiveness Analysis Registry.
Of the 497 published ICERs, 82% (n ¼ 406) evaluated guideline-
recommended interventions (e.g., diabetes retinopathy screen-
ing). The median value for all diabetes ICERs was roughly $17,200
per QALY gained ($15,400 per QALY gained when weighted by one
over the number of ratios reported by each ICER’s article)
compared with a median of $18,600 per QALY for all studies
cataloged in the Tufts Medical Center Cost-Effectiveness Analysis
Registry. Industry-sponsored interventions had a much lower
(more favorable) median value than did those sponsored by
nonindustry entities (roughly $12,400/QALY vs. $ 36,600/QALY).
A total of 20% (n ¼ 98) of diabetes-related ICERs were cost saving,
73% (n ¼ 355) were below the most often used threshold of
$50,000/QALY, and 6% (n ¼ 30) were dominated (less effective and
higher costs) (Fig. 2).eview. CEA, cost-effectiveness analysis; CUA, cost-utility
Table 1 – Characteristics of cost-utility studies of diabetes interventions.
Characteristic Primary (n ¼ 15) Secondary (n ¼ 43) Tertiary (n ¼ 138) All studies (n ¼ 196)
Year of publication
r1997* 0 (0) 0 (0) 7 (5) 7 (4)
1998–2002 2 (13) 6 (14) 6 (4) 14 (7)
2003–2007 3 (20) 20(47) 32 (23) 55 (28)
2008–2012 10 (67) 17 (40) 93 (67) 120 (61)
Study country
United States 6 (40) 21 (49) 53 (38) 80 (41)
United Kingdom 1 (7) 6 (14) 26 (19) 33 (17)
Canada 1 (7) 3 (7) 11 (8) 15 (8)
Sweden 1 (7) 2 (5) 7 (5) 10 (5)
The Netherlands 2 (13) 1 (2) 6 (4) 9 (5)
Other 4 (27) 10 (23) 35 (25) 49 (25)
Funding source
Industry 1 (7) 21 (49) 79 (57) 101 (52)
Nonindustry 9 (60) 13 (30) 31 (22) 53 (27)
No funding 1 (7) 1 (2) 8 (6) 10 (5)
Not disclosed 4 (27) 8 (19) 20 (15) 32 (16)
Type of intervention†
Pharmaceutical 1 (7) 18 (42) 88 (64) 107 (55)
Health education or behavior 7 (47) 11 (26) 16 (12) 34 (17)
Care delivery 2 (13) 6 (14) 25 (18) 33 (17)
Screening 6 (40) 16 (37) 3 (2) 25 (13)
Surgical 0 (0) 1 (2) 11 (8) 12 (6)
Diagnostic procedure 0 (0) 7 (16) 4 (3) 11 (6)
Medical device 0 (0) 1 (2) 10 (7) 11 (6)
Medical procedure 0 (0) 0 (0) 9 (7) 9 (5)
Other or NA 0 (0) 4 (9) 3 (2) 7 (4)
Immunization 1 (7) 0 (0) 0 (0) 1 (1)
Study perspective
Health care payer 7 (47) 27 (63) 106 (77) 140 (71)
Societal 6 (40) 11 (26) 15 (11) 32 (16)
Other or not speciﬁed 2 (13) 5 (12) 17 (12) 24 (12)
Presentation of
Time horizon 13 (87) 38 (88) 137 (99) 188 (96)
Intervention 15 (100) 40 (93) 137 (99) 192 (98)
Comparator 15 (100) 39 (91) 136 (99) 190 (97)
Target population 15 (100) 40 (93) 137 (99) 192 (98)
Sensitivity analysis
Yes 14 (93) 41 (95) 133 (96) 188 (96)
Note. Values are n (%).
CUA, cost-utility analysis; NA, not applicable/available.
* The ﬁrst diabetes CUA was published in 1994.
† Each article can have more than one intervention, and some interventions may fall under more than one type. Therefore, the percentages
may total more than 100.
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between each characteristic and the tendency for an ICER to
have a lower (e.g., more favorable) value than the sample
weighted median of $15,400 per QALY. The results showed, for
instance, that ICERs reported by a CUA conducted from a US
perspective were more likely to be favorable than other ratios
(odds ratio [OR] ¼ 2.82; 95% conﬁdence interval [CI] 1.40–5.70).
Interventions recommended by either the 2011 AACE guidelines
or the 2012 ADA standards were more likely to report favorable
ratios (OR ¼ 2.62; 95% CI 1.03–6.66). Ratios for surgical CUAs were
more favorable (OR ¼ 9.01; 95% CI 1.45–55.94) than other ratios.
ICERs reported by higher-quality studies (rating score Z4.5) were
more favorable than other ICERs (OR ¼ 2.39; 95% CI 1.19–4.81)
after controlling for other factors. Other study characteristics,
including sponsorship, prevention stage, study perspective, and
nonsurgical interventions, did not independently affect ICERs’
favorability.Step 2: Value of Shifting Patients to High-Value Treatments
Of the interventions considered in this systematic review, 98
were reported to be more effective and less expensive than their
comparators. Among these dominant interventions, 67 were
recommended by the AACE guidelines or the ADA standards.
Because we included studies conducted only from a US perspec-
tive, we retained only 15 of the 67 high-value interventions. For
our analysis, we ﬁnally identiﬁed 4 high-value interventions from
these 15 interventions that could be evaluated using the Humed-
ica data set, all of which were pharmaceutical treatments
(Table 2). (Use of interventions such as lifestyle changes and
diabetes-speciﬁc nutritional meal replacement could not be
directly determined from the Humedica data, given the lack of
information on these interventions in the data set.) Among the
four selected studies of these interventions, three were spon-
sored by industry [20–22]. The other study was government-
Fig. 2 – Distribution of ICERs (2012 US $). ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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either lifetime or 30 years.
Each year, about 41,000 patients in the Humedica data set were
diagnosed with type 2 diabetes and hypertension. Approximately
90% (n ¼ 37,593) of them received intensive hypertension control
that is deemed cost-saving. Similarly, most patients with type 2
diabetes (89%, n ¼ 13,894) were treated with pioglitazone plusTable 2 – Utilization of selected guidelines’ recommende
Humedica data sets.
Article Target population, interv
Palmer et al. [20] Target population
Patients with type 2 diabetes treated with
Intervention
Repaglinide plus metformin
Comparator
Nateglinide plus metformin
Valentine et al. [21] Target population
Patients with type 1 diabetes treated with
insulin aspart
Intervention
Insulin detemir plus insulin aspart
Comparator
Insulin glargine plus insulin aspart
St Charles et al. [22] Target population
Patients with type 2 diabetes treated with
metformin
Intervention
Pioglitazone plus metformin
Comparator
Rosiglitazone plus metformin
CDC Diabetes
Cost-effectiveness
Group [23]
Target population
People with type 2 diabetes and hypertens
Intervention
Intensive hypertension control (treatment
inhibitors or β-blockers)
Comparator
Moderate hypertension control (treatment
CDC, Centers for Disease Control and Prevention.metformin, a reportedly cost-saving therapy when compared with
rosiglitazone plus metformin. For patients with type 2 diabetes
taking combination therapy of meglitinides (including repaglinide
and nateglinide) plus metformin, however, only 55% (n ¼569) of
them were treated with the reportedly cost-saving drugs repaglinide
plus metformin. Utilization of the insulin detemir plus insulin aspart,
a reportedly cost-saving treatment, was even lower (14%, n ¼ 244) ford cost-saving interventions in US studies using
ention, and comparator Humedica
(n)
%
repaglinide or nateglinide plus metformin
569 54.7
472 46.3
insulin detemir or insulin glargine plus
244 13.6
1,553 86.4
pioglitazone or rosiglitazone plus
13,894 89.1
1,704 10.9
ion
37,593 90.0
with angiotensin-converting enzyme
4,178 10.0
with diet or other drugs)
Table 3 – Hypothetical resource reallocation scenarios: potential change in utilization, lifetime cost savings,
and QALYs gained.
Intervention Comparator Cost savings
per person*
QALYs gained
per person
Change in
utilization
Total cost
savings ($
million)*
Total
QALYs
gained
Repaglinide/
metformin
Nateglinide/
metformin
5115 0.14 47–425 0.24–2.17 6.58–59.50
Insulin detemir/
insulin aspart
Insulin glargine/
insulin aspart
2660 0.06 155–1398 0.41–3.72 9.30–83.88
Pioglitazone/
metformin
Rosiglitazone/
metformin
649 0.19 170–1534 0.11–1.00 32.30–291.46
Intensive
hypertension
control
Moderate
hypertension
control
1373 0.40 418–3760 0.57–5.16 167.20–
1504.08
Total 790–7117 1.33–12.49 215.38–
1938.92
QALY, quality-adjusted life-year.
* In 2012 US $.
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diabetes (86%, n ¼ 1553) received insulin glargine plus insulin aspart,
a therapy with higher costs and lower health beneﬁts. Results from
existing CER studies showed that cost-saving treatments also worked
better than or at least as well as their counterparts in terms of
both clinical efﬁcacy and the avoidance of major adverse drug events
[24–28].
Table 3 summarizes potential per-person cost savings and QALY
gains for the four cost-saving interventions, as well as the impact of
switching eligible patients to these therapies. The most cost-
effective intervention was insulin detemir plus insulin aspart,
saving $2660 and gaining 0.06 QALY per person. The potential for
shifting patients to high-value treatments was greatest for hyper-
tension control therapies; of the 4178 patients with this condition,
3760 patients (90%) could be shifted from moderate hypertension
control drugs (dominated treatments) to intensive hypertension
control drugs (cost-saving treatments). Across all treatments, as
many as an additional 7117 patients could be shifted to high-value
treatments (out of 7907 eligible), saving $12.5 million and gaining
1938.9 QALYs over a lifetime.Discussion
Our study sheds new light on CUAs evaluating treatments for
diabetes and its complications, which represent more than 5% of
all CUAs published over the years. The number of diabetes-
related CUAs published annually has consistently increased
during the past several decades. Most have focused on treatment.
More than half of the studies in our sample were conducted from
a US or UK perspective. Pharmaceutical and medical device
companies funded most of secondary and tertiary prevention
CUAs, whereas the government and nonproﬁt organizations were
the major funding sources for primary preventive measures.
More than half of all published diabetes CUAs evaluated phar-
maceutical treatments. Health care delivery, health education,
and preventive care programs, however, are more heavily repre-
sented in the diabetes CUA literature than in the CUA literature
in general [29].
Almost all diabetes-related studies followed guidelines for the
design and reporting of CUAs. They stated the study perspective
and time horizon, explicitly speciﬁed the target population, the
intervention, and the comparator, and performed the sensitivity
analysis. The average study quality for diabetes CUAs was
slightly higher than the corresponding average score for CUAsevaluating interventions for all diseases. Most of the studies
evaluated either AACE- or ADA-recommended interventions.
The median ICER reported by industry-sponsored CUAs was
lower (more favorable) than the corresponding median ICER
reported by other CUAs. This result may reﬂect more likely
publication of studies that yield a favorable ratio, or the use of
more favorable assumptions when articles are sponsored by
manufacturers [30]. Most ICERs were below the threshold of
£30,000 (roughly $50,000) per QALY used by the National Institute
for Health and Care Excellence [31]. Diabetes CUAs conducted
from a US perspective and studies with higher-quality scores
were more likely to report favorable ratios.
Although many studies have systematically reviewed eco-
nomic evaluations of diabetes interventions, our analysis adds to
the literature by estimating potential health and monetary gains
from shifting more patients to selected guideline-recommended
high-value interventions. Of the four high-value (cost-saving)
interventions for which we had utilization data from the Humed-
ica EMR data set, only two were used by more than half of the
eligible patients.
On the basis of results from both the CER and CUA literature,
we developed a simple scenario to evaluate cost savings and
health beneﬁt gains switching patients to high-value interven-
tions. Of 7907 eligible patients in our sample, up to 7117 could be
shifted to cost-saving treatments, saving more than $12 million
and gaining more than 1900 QALYs.
Our study has several limitations. First, we included only cost-
utility studies, which use QALYs to measure health outcomes,
although CEAs using other clinical measures of effectiveness are
also common. Second, our estimates of how many patients were
eligible for but not yet receiving high-value diabetes interven-
tions were based on the Humedica EMR data set. Information in
this database is limited to care from within Humedica’s provider
networks. In addition, the data did not contain information on all
cost-saving interventions. More complete data or other types of
data (e.g., Medicare) may be used in the future to generate more
comprehensive estimations. Third, saving estimates from
resource reallocation were based on CUAs published between
2002 and 2009. Information on both costs and effectiveness may
have changed since then. Fourth, our analysis of potential gains
from shifting to high-value services was based in part on results
from industry-sponsored studies from the US perspective, which
may be biased [30]. We also veriﬁed, however, the clinical
effectiveness and safety of our high-value interventions by
consulting the CER literature. Our results may be applied to other
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 0 8 – 3 1 4314countries if their guidelines do not differ signiﬁcantly from
American clinical guidelines.
Finally, our results should be interpreted with caution because we
assumed a range of patients who could be shifted to these therapies
from their currently used lower-value treatments. Our assumption
reﬂects patient tolerance of these high-value therapies, but other
factors, such as promotional advertising, ease of administration, and
patients’ co-payment, might constrain the shift of patients from lower-
value to high-value interventions [32,33].Conclusions
CEAs help to identify high-value services and hence help to
optimize health care spending [34–36]. Our ﬁndings suggest that
most diabetes interventions evaluated by CUAs were recom-
mended by practice guidelines and produced good value for
money (e.g., they cost o$50,000 per QALY gained). Our results
also indicate that practice is not economically optimal. Both
patients and the health care system could beneﬁt from shifting
to the greater use of services that have demonstrated greater
clinical effectiveness and lower costs. Future research is needed
to explore why cost-saving interventions are not fully utilized,
and whether there are patient characteristics that can explain or
at least predict the continued use of lower-value services.Acknowledgment
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